自发性高血压大鼠脑动脉心钠素受体分布的计量学研究

用软脑膜铺片技术,兔疫组织化学方法及全自动图像分析仪对１７周龄自发性高血压大鼠脑血管床心钠素受体分布密度进行研究、结果表明,自发性高血压大鼠脑小动脉及细动脉壁上心钠素受体分布密度明显低于正常血压大鼠,Ｐ＜０．０１。此外,在细小动脉分叉部位心钠素受体分布密度增加,而自发性高血压大鼠中其分叉部位的受体密度明显低于正常血压大鼠。从实验结果显示,我们试用的软脑膜铺片技术显然弥补了组织切片中从血管横断面观察心钠素受体分布的局限性,清楚地展现了整个血管床心钠素受体分布特征。根据实验结果提示这些阻力性动脉心钠素受体密度减少与细小动脉舒血管反应减弱,外周阻力增加,血压升高有着明显的关系;尤其是对调节外周循环血量和外周阻力充当闸门作用的细小动脉分叉部位,心钠素受体密度降低这一特征在高血压发生机制中可能起着重要作用。     

阿霉素肾病大鼠肌肉和静脉注射心钠素基因利尿作用的比较研究

为探讨心钠素基因经体细胞转移对阿霉素诱导的肾病动物泌尿功能的影响及其治疗肾病的潜力,采用肌肉或静脉内直接注射裸DNA的方法,将人心钠素基因的逆转录病毒载体分别导入阿霉素肾病动物体内,以期为其提供持续性的心钠素来源。结果发现,人心钠素基因经肌肉和静脉内直接注射这2 种途径导入后,均可使阿霉素肾病动物的尿量/体重比明显增加,有效利尿作用时间大于15d。试验期间,实验组肾病动物的体重明显增长,血浆中的心钠素浓度在基因转移5d 后明显升高,但动物尿中的K⁺和Na⁺浓度无明显变化。以上结果说明,心钠素基因经肌肉和静脉2 种途径导入均可明显改善肾病动物的泌尿功能,具有治疗肾病的潜力。     

慢性低氧时自发性高血压大鼠血浆心钠素、肾素—血管紧张素系统与血液动力学的变化

实验采用同龄自发性高血压大鼠(SHR)和Wistar-Kyoto大鼠(WKY),各随机分为对照组(N)和低氧组(H)。实验前 SHR 尾动脉压(25.4±2.6kPa,n=20)明显高于WKY(13.1±1.6kPa,n=20),P<0.001。SHR-N组血浆心钠素(ANP)、血管紧张素Ⅱ(AⅡ)含量和肾素活性(RA)明显高于WKY-N。SHR-N经实验两周后血压自然上升(P<0.01)。SHR和WKY缺氧后ANP、AⅡ、RA各值均比各自对照值增加,但血压无明显改变.而肺动脉压均明显升高。以上结果提示,SHR 大鼠慢性缺氧后,ANP和肾素-血管紧张素系统可能对防止血压上升和限制肺动脉高压进一步发展起一定的调节作用。     

慢性缺氧对自发性高血压大鼠血液动力学和血管反应性的影响

本研究观察了鼠龄10周的自发性高血压大鼠(SHR)在慢性缺氧条件下(模拟海拔5000m,15d)体动脉压(SBP)、平均肺动脉压(MPAP)、左、右心室收缩指数(LVIC、RVIC)和舒张指数(LVIR、RVIR)以及血管反应性的变化。结果表明,慢性缺氧明显阻抑SHR大鼠SBP升高(P<0.05),但使SHR大鼠MPAP升高(P<0.001)。慢性缺氧还可增大SHR大鼠LVIC和LVIR,增强SHR大鼠胸主动脉对乙酰胆碱(ACh)的舒张反应,减弱其对5-羟色胺(5-HT)的收缩反应。SHR大鼠肺动脉对ACh和5-HT的反应则与主动脉相反。实验结果提示,慢性缺氧阻抑SHR大鼠血压升高与血管反应性的改变有关。     

内源性中枢血管紧张素Ⅱ在慢性应激大鼠血压高反应性中的作用

心理生理学研究表明,高血压病人对应激刺激的反应性要高于正常血压者,高血压息者对刺激产生的血压变化在幅度与时限上均强于正常血压者。动物实验表明,与Wistar-Kyoto(WKY)大鼠相比,自发性高血压大鼠(SHR)对环境心理应激的心血管反应性增强,并可能与遗传有关。在SHR的高血压维持中血管紧张素Ⅱ(AⅡ)起一定作用。本实验探讨内源性中枢AⅡ在慢性应激Wistar大鼠动脉血压高反应     

自发性高血压大鼠(STIR)血压检测资料

测定香港大学实验动物中心所饲养的自发性高血压大鼠(SHR)的血压,以掌握其血压数据及变化情况,并确定它们是否保持其高血压特征。1 材料和方法42只清洁级大鼠,其中实验组(SHR)16只,对照组(WKY)10只,参考组SHR 10只,     

心钠素在强啡肽降压效应中的作用

前已报道,吗啡能刺激心钠素的释放。本文报告,静注强啡肽可引起大鼠血压的降低,这一作用可为纳洛酮和抗心钠素IgG预处理所阻断。静注强啡肽可引起大鼠血浆中心钠素水平升高和心房心钠素的下降。实验结果提示,强啡肽的降压效应可能由心房中心钠素释放所致。     

自发性高血压大鼠中枢去甲肾上腺素与血管紧张素Ⅱ的含量及相互关系

用荧光分光与放射免疫法,分别测定自发性高血压大鼠(SHR)与正常血压 WKY:大鼠脑内不同部位的去甲肾上腺素(NE)与血管紧张素Ⅱ(AⅠ)的含量。用尾筒法测量清醒大鼠尾动脉压。结果发现第8周龄 SHR 的血压及延脑、脑桥、下丘脑与尾核 NE 与 A Ⅱ含量和同龄WKY 相比,无明显差异。第12周龄以后,SHR 的血压逐渐升高,至20周龄时不再升高,维持在接近16周龄时的水平。可是 WKY 的血压无明显变化。在血压升高的早期与后期SHR 延脑、脑桥、下丘脑及尾核内 AⅡ含量显著高于 WKY,但 NE 的含量变化却不同,在早期与 WKY 有明显差异,而在高血压的后期无明显差异。提示在 SHR 高血压的早期 NE与 A Ⅱ均起作用,而在后期只 A Ⅱ起作用。向 SHR 侧脑室分别注射 Captopril 与6-OHDA,均引起血压下降,延脑与下丘脑内 AⅡ与 NE 含量均下降,两者表现同向关系。SHR 脑内AⅡ与 NE 这种同向变化在高血压的发生中可能起重要作用。     

正常大鼠植入高血压大鼠肾脏后动脉血压的变化

本实验对12周龄的自发性高血压大鼠(spontaneouslyhypertensiverat,SHR)及其对照组WistarKyoto(WKY)大鼠进行了肾脏移植的研究,并观察受肾移植大鼠动脉血压的变化以及免疫抑制剂对动脉血压的影响。用尾套法对接受同窝另一同胞WKY大鼠肾脏移植且存活5周的6只WKY大鼠(A组)及接受SHR肾脏移植且存活5周的6只WKY大鼠(B组)的尾动脉收缩压进行检测,移植前A、B两组受肾移植大鼠的尾动脉收缩压分别为180±093和183±068kPa,无统计学显著差异(P>005);移植后3、4、5周时,B组大鼠的尾动脉收缩压显著高于A组大鼠,移植后5周时,A,B两组大鼠的收缩压分别为190±071和230±069kPa(P<0001);所用剂量的免疫抑制剂CsA对双侧肾脏完整以及右侧肾脏切除的SHR、WKY大鼠的动脉血压无显著影响。以上结果表明,SHR的肾脏在高血压的形成中可能起重要作用     

正常大鼠植入高血压大鼠肾脏后 动脉血压的变化

本实验对12周龄的自发性高血压大鼠(spontaneously hypertensive rat,SHR)及其对照组Wistar Kyoto (WKY)大鼠进行了肾脏移植的研究, 并观察受肾移植大鼠动脉血压的变化以及免疫抑制剂对动脉血压的影响。 用尾套法对接受同窝另一同胞WKY大鼠肾脏移植且存活5周的6只WKY大鼠(A组)及接受SHR肾脏移植且存活5周的6只WKY大鼠(B组)的尾动脉收缩压进行检测, 移植前A、 B两组受肾移植大鼠的尾动脉收缩压分别为18.0±0.93 和18.3±0.68 kPa,无统计学显著差异(P>0.05); 移植后3、 4、 5周时, B组大鼠的尾动脉收缩压显著高于A组大鼠, 移植后5周时, A, B两组大鼠的收缩压分别为19.0±0.71 和23.0±0.69 kPa (P<0.001); 所用剂量的免疫抑制剂CsA对双侧肾脏完整以及右侧肾脏切除的SHR、 WKY大鼠的动脉血压无显著影响。 以上结果表明, SHR的肾脏在高血压的形成中可能起重要作用。     

厄贝沙坦对人脐静脉内皮细胞株EA.hy926增殖、凋亡、VEGF mRNA表达的影响

目的:应用不同浓度厄贝沙坦对人脐静脉内皮细胞株EA.hy 926的增殖、凋亡生物学效应及血管发生主要基因VEGFmRNA的表达进行体外研究,探讨厄贝沙坦对内皮细胞的血管生成效应。方法:各种浓度厄贝沙坦对人脐静脉内皮细胞株EA.hy926共同孵育24 h。细胞增殖采用CCK8法分析,Annexin V/PI双染法检测细胞凋亡。RT-PCR验证VEGFmRNA的表达。结果:厄贝沙坦各浓度干预组细胞形态无明显变化,CCK8结果提示厄贝沙坦各干预组相比对照组细胞增殖活力增高(P<0.05),呈浓度非依赖性。流式细胞仪分析厄贝沙坦各浓度干预组细胞无明显凋亡。RT-PCR发现厄贝沙坦1×10-4,1×10-5,1×10-6mol/L浓度组VEGFmRNA表达增高(P<0.05)。结论:厄贝沙坦促进EA.hy926细胞株细胞增殖,上调VEGFmRNA的表达。这提示除了降压效应,血管紧张素受体拮抗剂在缺血性心脏病如慢性心力衰竭治疗中具有一定作用。     

Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis

A new hematopoietic cell line, designated KCL-22, was established in vitro by cultivation of pleural effusion cells obtained from a woman with chronic myelogenous leukemia in blast crisis. KCL-22 grew in suspension culture with a doubling time of 24 h and consisted of immature undifferentiated cells which were positive for periodic acid-Schiff and acid phosphatase staining. Chromosome analysis of the KCL-22 line showed a female karyotype with double Ph1 chromosomes and additional chromosome abnormalities. Its representative karyotype was 52,XX, + 1p-,+6,+8,+8,+8, t(9q+;22q-), +22q-. This cell line possessed receptors for the Fc portion of IgG, but lacked lymphoid cell characteristics and the Epstein-Barr virus-associated nuclear antigen. These results indicate that the KCL-22 cells were derived from chronic myelogenous leukemia cells. This cell line should prove useful for research involving various aspects of chronic myelogenous leukemia.     

Hepatitis C--new developments in the studies of the viral life cycle

Hepatitis C virus (HCV) is a causative agent of chronic liver disease leading to cirrhosis, liver failure and hepatocellular carcinoma. The prevalence of HCV is estimated as 3% of the world population and the virus is a major public health problem all over the world. For over 16 years, since HCV had been discovered, studies of the mechanisms of the viral life cycle and virus-host interactions have been hampered by the lack of a cell culture system allowing the virus to be grown in laboratory conditions. However, in recent years some new model systems to study HCV have been developed. The major breakthrough of the last two years was the cell culture system for maintaining the virus in an adapted hepatocyte-derived cell line. This review describes the techniques and applications of most of the in vitro systems and animal models currently used for working with hepatitis C virus.     

Gefitinib-mediated Reactive Oxygen Specie (ROS) Instigates Mitochondrial Dysfunction and Drug Resistance in Lung Cancer Cells

Therapeutic benefits offered by tyrosine kinase inhibitors (TKIs), such as gefitinib (Iressa) and erlotinib (Tarceva), are limited due to the development of resistance, which contributes to treatment failure and cancer-related mortality. The aim of this study was to elucidate mechanistic insight into cellular perturbations that accompany acquired gefitinib resistance in lung cancer cells. Several lung adenocarcinoma (LAD) cell lines were screened to characterize epidermal growth factor receptor (EGFR) expression and mutation profile. To circumvent intrinsic variations between cell lines with respect to response to drug treatments, we generated gefitinib-resistant H1650 clone by long-term, chronic culture under gefitinib selection of parental cell line. Isogenic cells were analyzed by microarray, Western blot, flow cytometry, and confocal and transmission electron microscope. We observed that although chronic gefitinib treatment provided effective action against its primary target (aberrant EGFR activity), secondary effects resulted in increased cellular reactive oxygen species (ROS). Gefitinib-mediated ROS correlated with epithelial-mesenchymal transition, as well as striking perturbation of mitochondrial morphology and function. However, gefitinib treatment in the presence of ROS scavenger provided a partial rescue of mitochondrial aberrations. Furthermore, withdrawal of gefitinib from previously resistant clones correlated with normalized expression of epithelial-mesenchymal transition genes. These findings demonstrate that chronic gefitinib treatment promotes ROS and mitochondrial dysfunction in lung cancer cells. Antioxidants may alleviate ROS-mediated resistance.     

Serum beta-N-acetyl hexosaminidase levels in chronic renal failure

Serum beta-N-acetyl hexosaminidase (beta-NAH) levels, the indirect indicators of hepatic endothelial and Kupffer cell function, were examined in 16 anuric chronic hemodialysis patients, and in 11 patients in different stages of chronic renal failure (serum creatinine 2-8.8 mg/dl). They were found to be lower than those of the healthy controls, contrary to expectation. It might be concluded that nonparenchymal liver cells are functioning well in chronic renal failure. However, the possibility that production of beta-NAH in these patients is abnormally reduced cannot be excluded.     

A Lentiviral Gene Therapy Strategy for the In Vitro Production of Feline Erythropoietin

Nonregenerative anemia due to chronic renal failure is a common problem in domestic cats. Unfortunately, administration of recombinant human erythropoietin often only improves anemia temporarily due to antibody development. In this in vitro study, feline erythropoietin cDNA was cloned from feline renal tissue and utilized in the construction of a replication-defective lentiviral vector. The native recombinant feline erythropoietin (rfEPO) sequence was confirmed by sequencing. Upon viral vector infection of human 293H cells, Crandall Renal Feline Kidney cell line and primary feline peripheral blood mononuclear cells, bioactive rfEPO protein was produced. The presence of cellular rfEPO cDNA was confirmed by standard PCR, production of abundant rfEPO mRNA was confirmed by real-time PCR, and secretion of rfEPO protein was demonstrated by Western blot analyses, while rfEPO protein bioactivity was confirmed via an MTT proliferation bioassay. This in vitro study demonstrates the feasibility of a replication-defective lentiviral vector delivery system for the in vitro production of biologically active feline erythropoietin. Anemic cats with chronic renal failure represent a potential in vivo application of a lentiviral gene therapy system.     

The purine nucleotide content in human leukemia cell lines

The HPLC method was used to determine the purine nucleotide (ATP, ADP, AMP, GTP, GDP, GMP, NAD(+)) contents and the values of the adenylate energy charge (AEC) and guanylate energy charge (GEC) for three human acute myelogenous leukemia (AML) cell lines: HL60 (M3 subtype of AML), THP1 (M5 subtype of AML), and HEL (M6 subtype of AML) in French-American-British classification (FAB) and for one chronic myelogenous leukemia (CML) cell line: K562. The results showed that the examined leukemic cells had some significant changes in their purine nucleotide concentrations relative to healthy cells. On the basis of the obtained results, it seems that two of the tested acute myelogenous leukemia cell lines, HL60 and HEL, have similar purine nucleotide metabolisms, while the third AML cell line, THP1, has a purine nucleotide metabolism like that of the chronic myelogenous leukemia cell line, K562.     

One in vitro model for visceral adipose-derived fibroblasts in chronic inflammation

One pathogenesis of the obesity-associated complications is that consistent with increased body fat mass, the elevation of adipose tissue-derived cytokines inflicts a low-grade chronic inflammation, which ultimately leads to metabolic disorders. Adipocytes and macrophages in visceral adipose (VA) have been confirmed to contribute to the chronic inflammation; however, the role of the resident fibroblasts is still unknown. We established one VA fibroblast cell line, termed VAFC. Morphological analysis indicated that there were large numbers of pits at the cell plasma membrane. In vitro VAFC cells promoted bone marrow cells to differentiate into macrophages and protected them from apoptosis in the serum-free conditions. Additionally, they also interfered in lymphocytes proliferation. On the basis of these results, this cell line might be an in vitro model for understanding the role of adipose-derived fibroblasts in obesity-associated chronic inflammation.     

Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line

Nilotinib is approved for treatment of newly diagnosed chronic myeloid leukemia (CML) and it is shown superiority over imatinib in first-line treatment for patients of CML. In this study, we established a nilotinib-resistant cell line, K562NR, and evaluated the resistance to nilotinib and efficacy of dasatinib. We found activation of Lyn plays a dominant role in survival of the nilotinib-resistant cell line. We found dasatinib induces the apoptosis of nilotinib-resistant cells and inhibits Lyn kinase activity. This novel nilotinib-resistant CML cell line may help to explore novel therapy for CML.